Could a common arthritis drug tame rare immune disease Flare-Ups?
NCT ID NCT05104723
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug tofacitinib (Xeljanz) in 10 adults with chronic granulomatous disease (CGD) who had ongoing inflammation in the gut, skin, or lungs. Participants took the pill daily for 3 months to see if it was safe and could help control symptoms. The goal was to find a better option for people who don't respond well to current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tofacitinib (Xeljanz)
- What this could lead to
- If it works, this could point toward a new treatment option for people with chronic granulomatous disease who have ongoing inflammation.
- What could go wrong
- This is a very small, early-phase study with only 10 participants, so results may not apply to everyone. Tofacitinib can increase infection risk, which is especially concerning for people with CGD.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGD-RELATED INFLAMMATORY SKIN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Newborn screening study aims to catch rare diseases at birth
- Gene fix for rare immune disease: can it stop deadly infections?
- Groundbreaking gene therapy aims to fix immune system in rare disease
- New hope for CGD: stem cell transplant trial aims for a cure
- Milder stem cell transplant shows promise for kids with immune disorders